Cargando…

Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates

Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Roos M., Singh, Susheel K., Teelen, Karina, van de Vegte-Bolmer, Marga, van Gemert, Geert-Jan, Stone, Will J. R., Locke, Emily, Plieskatt, Jordan, Theisen, Michael, Bousema, Teun, Jore, Matthijs M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259988/
https://www.ncbi.nlm.nih.gov/pubmed/35812379
http://dx.doi.org/10.3389/fimmu.2022.909060
_version_ 1784741913171066880
author de Jong, Roos M.
Singh, Susheel K.
Teelen, Karina
van de Vegte-Bolmer, Marga
van Gemert, Geert-Jan
Stone, Will J. R.
Locke, Emily
Plieskatt, Jordan
Theisen, Michael
Bousema, Teun
Jore, Matthijs M.
author_facet de Jong, Roos M.
Singh, Susheel K.
Teelen, Karina
van de Vegte-Bolmer, Marga
van Gemert, Geert-Jan
Stone, Will J. R.
Locke, Emily
Plieskatt, Jordan
Theisen, Michael
Bousema, Teun
Jore, Matthijs M.
author_sort de Jong, Roos M.
collection PubMed
description Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology.
format Online
Article
Text
id pubmed-9259988
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92599882022-07-08 Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates de Jong, Roos M. Singh, Susheel K. Teelen, Karina van de Vegte-Bolmer, Marga van Gemert, Geert-Jan Stone, Will J. R. Locke, Emily Plieskatt, Jordan Theisen, Michael Bousema, Teun Jore, Matthijs M. Front Immunol Immunology Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259988/ /pubmed/35812379 http://dx.doi.org/10.3389/fimmu.2022.909060 Text en Copyright © 2022 de Jong, Singh, Teelen, van de Vegte-Bolmer, van Gemert, Stone, Locke, Plieskatt, Theisen, Bousema and Jore https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
de Jong, Roos M.
Singh, Susheel K.
Teelen, Karina
van de Vegte-Bolmer, Marga
van Gemert, Geert-Jan
Stone, Will J. R.
Locke, Emily
Plieskatt, Jordan
Theisen, Michael
Bousema, Teun
Jore, Matthijs M.
Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title_full Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title_fullStr Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title_full_unstemmed Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title_short Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates
title_sort heterologous expression and evaluation of novel plasmodium falciparum transmission blocking vaccine candidates
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259988/
https://www.ncbi.nlm.nih.gov/pubmed/35812379
http://dx.doi.org/10.3389/fimmu.2022.909060
work_keys_str_mv AT dejongroosm heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT singhsusheelk heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT teelenkarina heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT vandevegtebolmermarga heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT vangemertgeertjan heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT stonewilljr heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT lockeemily heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT plieskattjordan heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT theisenmichael heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT bousemateun heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates
AT jorematthijsm heterologousexpressionandevaluationofnovelplasmodiumfalciparumtransmissionblockingvaccinecandidates